Nov 1, 2010-- Skyentia Technologies LLC announced today that it has been awarded over $260,000 in qualified investment grants and funding through the Qualified Therapeutic Discovery Program.
The President of the company, Dr. Richard J. McMurtrey, announced the certification of over a quarter million dollars in qualified grants late Monday, stating, "The receipt of these funds will greatly advance our extensive work in creating new solutions to unsolved problems in medicine and science."
Skyentia Technologies was founded in November 2009 and is a company focused on several research and development projects pertaining to both biotechnology and medical devices. This includes projects such as the discovery of novel therapeutic agents and strategies for neuroprotection in stroke and traumatic brain injury, the development of implantable therapeutic systems, and the development of non-invasive monitoring interfaces and diagnostic systems.
More information can be obtained at their website www.skyentia.com.
Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties.
There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company.
These factors include, but are not limited to:
(1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.